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Abstract
Without medical progress, dementing diseases such as Alzheimer’s disease will become one of the main causes of disability. Preventing or
delaying them has thus become a real challenge for biomedical research. Steroids offer interesting therapeutical opportunities for promoting
successful aging because of their pleiotropic effects in the nervous system: they regulate main neurotransmitter systems, promote the viability
of neurons, play an important role in myelination and influence cognitive processes, in particular learning and memory. Preclinical research
has provided evidence that the normally aging nervous system maintains some capacity for regeneration and that age-dependent changes
in the nervous system and cognitive dysfunctions can be reversed to some extent by the administration of steroids. The aging nervous
system also remains sensitive to the neuroprotective effects of steroids. In contrast to the large number of studies documenting beneficial
effects of steroids on the nervous system in young and aged animals, the results from hormone replacement studies in the elderly are so
far not conclusive. There is also little information concerning changes of steroid levels in the aging human brain. As steroids present in
nervous tissues originate from the endocrine glands (steroid hormones) and from local synthesis (neurosteroids), changes in blood levels
of steroids with age do not necessarily reflect changes in their brain levels. There is indeed strong evidence that neurosteroids are also
synthesized in human brain and peripheral nerves. The development of a very sensitive and precise method for the analysis of steroids by
gas chromatography/mass spectrometry (GC/MS) offers new possibilities for the study of neurosteroids. The concentrations of a range of
neurosteroids have recently been measured in various brain regions of aged Alzheimer’s disease patients and aged non-demented controls
by GC/MS, providing reference values. In Alzheimer’s patients, there was a general trend toward lower levels of neurosteroids in different
brain regions, and neurosteroid levels were negatively correlated with two biochemical markers of Alzheimer’s disease, the phosphorylated
tau protein and the -amyloid peptides. The metabolism of dehydroepiandrosterone has also been analyzed for the first time in the aging
brain from Alzheimer patients and non-demented controls. The conversion of dehydroepiandrosterone to5-androstene-3,17-diol and to
7-OH-dehydroepiandrosterone occurred in frontal cortex, hippocampus, amygdala, cerebellum and striatum of both Alzheimer’s patients
and controls. The formation of these metabolites within distinct brain regions negatively correlated with the density of -amyloid deposits.
© 2003 Elsevier Ltd. All rights reserved.
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1. Introduction
In the developed countries, with the considerable increase
in life expectancy, the number of older people will soon sur-
pass that of the younger. This evolution in demography has
increased the need for the development of new therapeutical
strategies to promote successful aging, defined as low prob-
ability of disease, high cognitive and physical capacity and
active engagement in life (Rowe and Kahn, 1997; Le Fur
et al., 2002). Dementia and in particular Alzheimer’s dis-
ease (AD), the prevalence of which dramatically increases
during aging, will affect a growing number of people and
will become one of the main causes of disability among the
elderly and a major public health problem (Hebert et al.,
2001; Hauw and Duyckaerts, 2002; Sloane et al., 2002).
Without progress in preventing or delaying onset of AD,
both the number of people with AD disease and the propor-
tion of the total population affected will increase substan-
tially. Epidemiological studies predict that more than 33%
of women and 20% of men aged 65 years and older will
develop dementia, and by the year 2050, cases of demen-
tia will approach the number of cases of cancer (Ott et al.,
1998).
Projections indicate that therapies that simply delay the
onset of AD will markedly reduce overall disease preva-
lence. This is a consequence of the exponential rise in preva-
lence and incidence of AD with age (Sloane et al., 2002). It
has been estimated that delaying the onset of AD by only 5
years would decrease its prevalence by as much as a half (Le
Fur et al., 2002). Developing preventive strategies has thus
become a main concern. Much effort is actually devoted to
the elucidation of the cellular and molecular mechanisms
involved in the development of age-dependent dysfunctions
and degenerative diseases of the nervous system. It is obvi-
ous that multiple factors are involved, involving the genetic
background and the environment (Amouyel, 2002). With
respect to the prevention of dementia, there is particular in-
terest in the treatment of mild cognitive impairment (MCI),
which frequently progresses to dementia (Petersen et al.,
2001).
The important question then is whether prevention or
treatment of age-dependent nervous dysfunctions and of
the resulting cognitive impairments is possible. Recent
neuromorphological studies using stereological techniques
for counting neuron numbers have provided encouraging
news in this respect. They have provided compelling evi-
dence that the loss of neurons during normal aging is much
less than previously thought and that cognitive decline ob-
served in aged monkeys and humans is not primarily due
to the loss of cortical or hippocampal neurons (Wickelgren,
1996a,b; Peters et al., 1998; Peters, 2002). In the hippocam-
pus and entorhinal cortex, two vulnerable brain regions
that are critically involved in memory processes, a massive
loss of neurons is only observed in patients with dementia
(Gomez-Isla et al., 1996; West et al., 2000). Changes in the
aging brain mainly affect cell functions, the size of neu-
rons, the density of neurites and the number of synapses.
Alterations of the integrity of myelin sheaths and myelin
loss are particularly reliable markers of the aging nervous
system and correlate with cognitive decline (Peters, 1996,
2002).
Because changes in the aging nervous system are subtle,
it may be possible to reverse them and to improve cognitive
performance by pharmacological treatments. The adminis-
tration of steroids may be particularly promising in this re-
gard: (1) they play an important role in the functioning of
the central and peripheral nervous system (CNS and PNS);
(2) some steroids have neuroprotective effects; (3) the levels
of some neuroactive steroids markedly decrease with age;
and (4) unconjugated steroids easily cross the blood–brain
barrier and rapidly accumulate throughout the brain. It is
indeed now well recognized that the functions of gonadal
and adrenal steroid hormones go far beyond reproduction
and that they regulate vital neuronal and glial functions by
a variety of mechanisms of action (Schumacher and Robert,
2002; Schumacher et al., 2000). In addition, some steroids,
named “neurosteroids,” can be synthesized within the ner-
vous system by both neurons and glial cells, and the stimula-
tion of their synthesis offers new therapeutical possibilities
(Baulieu, 1997; Robel et al., 1999).
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In this review, we shall first describe the multiple effects
of steroids in the nervous system, which may be relevant
for the aging process. We shall then examine the steroidal
aging in humans and present evidence that neurosteroids
may also be synthesized within the human nervous sys-
tem. After a brief survey of recent preclinical evidence that
age-dependent dysfunctions of the nervous system can be
reversed by the administration of steroids, we shall provide
an update of hormone replacement therapy (HRT) in hu-
mans. The chapter will conclude with a discussion of pos-
sible therapeutical strategies involving steroids.
2. Pleiotropic effects of steroids in the nervous system
with significance for the aging nervous system
A large number of animal studies support the beneficial
effects of estradiol on the functioning and viability of neu-
rons and on learning and memory processes (Garcia-Segura
et al., 2001; McEwen, 2001). This steroid, derived from ei-
ther the circulation or from the local aromatization of an-
drogens, is also thought to play an important role in aging
of the brain and of cognitive processes. The potential use-
fulness of estrogens in preventing or treating age-dependent
brain dysfunctions has thus become a major issue.
The neuroprotective effects of estrogens have been doc-
umented by many in vivo and in vitro studies. In aged an-
imals and in different lesion paradigms, the treatment with
estradiol enhances neuronal survival and recovery (Tanzer
and Jones, 1997; Callier et al., 2000; Wise et al., 2000;
Garcia-Segura et al., 2001). In culture, estradiol protects neu-
rons against excitatory amino acid and -amyloid peptide
toxicity, oxidative stress and glucose deprivation (Ferreira
and Caceres, 1991; Lorenzo et al., 1992; Behl et al., 1997;
Goodman et al., 1996; Green et al., 2000; Zhang et al.,
2001). More recently, estradiol has also been shown to pro-
mote neurogenesis within the adult hippocampal formation
(Gould et al., 2000). An observation that may be particularly
relevant for AD is the decreased generation of -amyloid
peptides by neuroblastoma cells and by primary cultures
of rat, mouse and human embryonic cerebrocortical neu-
rons (Xu et al., 1998). Decreased levels of estrogen in post-
menopausal women could thus contribute to the increased
risk for the development of neurodegenerative diseases.
Like the estrogens, progestins are also pleiotropic hor-
mones in nervous system and exert neuroprotective effects.
In the rat spinal cord, progesterone (PROG) promotes neu-
rological and functional recovery after contusion injury
(Thomas et al., 1999) and promotes the survival of ventral
motoneurons in the wobbler mouse, a genetic model of
spinal cord motor disease (Gonzalez Deniselle et al., 2002).
PROG also increases the survival of facial motoneurons af-
ter axotomy (Yu, 1989). Particularly remarkable protective
effects of PROG have been documented in the rat brain
after traumatic injury, which explains why female rats have
significantly less edema and show better cognitive recovery
than males (Stein, 2001). PROG has also been shown to
offer neuroprotection after cerebral ischemia (Jiang et al.,
1996).
In addition to its protective effects on nerve cells, PROG
is also a signaling molecule involved in the formation of new
myelin sheaths, which are necessary for the efficient and
rapid conduction of action potentials. This function of PROG
is also of significance for the aging brain and peripheral
nerves, characterized by the loss of myelin (Peters, 2002).
A role of PROG in myelination has first been observed in
peripheral nerves, where PROG synthesized by Schwann
cells promotes the formation of new myelin sheaths after
lesion. Increased myelin formation in response to PROG has
also been demonstrated in explant cultures of embryonic rat
dorsal root ganglia (DRG), mainly composed of Schwann
cells and sensory neurons (Koenig et al., 1995; Schumacher
et al., 2001). In this cell culture system, PROG has been
shown to accelerate myelin synthesis (Chan et al., 1998).
Progestins regulate myelination in peripheral nerves via
two distinct signaling mechanisms, involving either the in-
tracellular PROG receptor (PR) or membrane GABAA re-
ceptors, which are both expressed by Schwann cells. These
two receptor systems are involved in the expression of dis-
tinct major peripheral myelin proteins, namely, protein zero
(P0) and peripheral myelin protein 22 (PMP22). PROG and
5-dihydroprogesterone, which both bind with high affinity
to the intracellular PR, increase expression of P0 expres-
sion via this receptor, whereas 3,5-TH PROG increases
PMP22 expression by modulating Schwann cell GABAA
receptors (Melcangi et al., 1999; Magnaghi et al., 2001).
Both P0 and PMP22 are encoded by dosage-sensitive genes
and are major culprits in motor and sensory neuropathies,
which show an increased frequency in the elderly (Suter and
Snipes, 1995; Suter and Nave, 1999).
PROG also stimulates myelination by oligodendrocytes
in the CNS. This has been shown in organotypic slice cul-
tures of 7-day-old rat and mouse cerebellum. When added
to the culture medium, PROG accelerated myelin forma-
tion in explant cultures of both males and females. The
effect of PROG on myelination involved the intracellular
PR: it could be blocked by the PR antagonist mifepristone
(RU486), and PROG had no significant effect on myelina-
tion in cerebellar slice cultures from PR knockout mice. As
in the PNS, 3,5-TH PROG also promoted myelination in
a bicuculline-sensitive manner involving GABAA receptors.
However, as the explant cultures contained many cell types,
it is unknown whether 3,5-TH PROG acted on neuronal
or glial GABAA receptors (Ghoumari et al., 2003).
The non-reproductive effects of androgens in the nervous
system are considerably less well characterized than those
of estrogens and progestins. Testosterone influences neu-
roplastic changes in different nuclei of the limbic system
(Johnson et al., 1989; Malsbury and McKay, 1994; De Vries
et al., 1994) and also exerts neuroprotective effects, which
can be mediated either directly or indirectly via its arom-
atization to estradiol (Balthazart and Ball, 1998). Work on
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different rodent motoneuron populations, including facial,
spinal and pudendal motoneurons, has demonstrated that
the administration of testosterone immediately after nerve
injury promotes their survival and regeneration through ac-
tions mediated by the androgen receptor (Tanzer and Jones,
1997; Jones et al., 2001). Physiological concentrations
of testosterone have also been shown to protect primary
cultures of human neurons against apoptosis induced by
serum deprivation. The effect of testosterone was directly
mediated through androgen receptors and did not involve
its aromatization to estradiol: (1) it could be mimicked by
the non-aromatizable androgen mibolerone; (2) it could be
blocked by the antiandrogen flutamide; and (3) it was not
prevented by an aromatase inhibitor (Hammond et al., 2001).
Testosterone also regulates the production of -amyloid pep-
tides by neurons. Treatment of neuroblastoma cells and of rat
primary cerebrocortical neurons with testosterone increases
the secretion of the non-amyloidogenic -amyloid precur-
sor protein (APP) fragment and decreases the secretion of
amyloidogenic -amyloid peptides (Gouras et al., 2000).
Androgens also play a role in myelination and have
been shown to modulate P0 gene expression in the PNS.
As Schwann cells do not express the intracellular an-
drogen receptor, different alternative mechanisms by
which androgens regulate peripheral myelin gene expres-
sion have been proposed: (1) the testosterone metabolite
5-dihydrotestosterone may activate P0 expression by in-
teracting with the PR, which is present in Schwann cells;
(2) the testosterone metabolite 3,5-androstane-diol may
interact with GABAA receptors; and (3) testosterone may
influence the myelination process indirectly by acting on
the neurons that are myelinated (Magnaghi et al., 1999).
The precursor steroids of estrogens, progestins and
androgens, pregnenolone (PREG) and dehydroepiandros-
terone (DHEA), also influence neuronal functions and are
likely to play a particularly important role in the aging
nervous system. Thus, PREG protects mouse hippocampal
cells against glutamate and -amyloid peptide-induced cell
death in a concentration dependent manner. Prevention of
glucocorticoid receptor (GR) translocation into the nucleus
may be involved in the observed neuroprotective effects of
PREG against glutamate neurotoxicity (Gursoy et al., 2001).
When administered in vivo, PREG reduced histopatho-
logical changes, saved the nervous tissue from secondary
lesions and improved the recovery of motor functions after
spinal cord injury (Guth et al., 1994). PREG may exert
its neuroprotective effects indirectly via its conversion to
PROG or by acting directly on spinal cord neurons. Indeed,
although PREG is generally considered as a precursor for
biologically active steroids, a recent study has shown that
PREG itself may influence the dynamics of the neuronal cy-
toskeleton by binding to the microtubule-associated protein
2 (MAP-2; Murakami et al., 2000).
The sulfated form of PREG (PREGS) is a potent steroidal
enhancer of memory processes in rodents (Isaacson et al.,
1995; Mayo et al., 1993; Ladurelle et al., 2000). It has
been shown to prevent amnesia induced by pharmacological
agents (Flood et al., 1992, 1995; Mathis et al., 1994, 1996)
and to reverse age-dependent memory deficits (Vallée et al.,
1997). The mechanisms underlying the promnesic actions of
PREGS involve the modulation of neurotransmitter systems,
including the N-methyl-d-aspartate (NMDA)-glutamatergic
system (Mathis et al., 1994; Maurice et al., 1998; Akwa
et al., 2001), 1 receptors (Urani et al., 1998; Reddy and
Kulkarni, 1998) and the central cholinergic system (Meziane
et al., 1996; Darnaudéry et al., 1998). It has been pro-
posed that PREGS may stimulate cholinergic neurotrans-
mitter pathways that are critically involved in learning and
memory by inhibiting the GABAergic innervation of cholin-
ergic forebrain neurons, resulting in enhanced acetylcholine
release within the cerebral cortex, amygdala and hippocam-
pus (Darnaudéry et al., 1998; Pallarés et al., 1998; Vallée
et al., 2001).
A large number of animal studies have documented ben-
eficial effects of DHEA on obesity, diabetes, cancer, heart
disease, immune and nervous functions (Bellino et al., 1995;
Kalimi and Regelson, 1990). With respect to the latter, the
neurotrophic and neuroprotective effects of DHEA and its
sulfate DHEAS have been documented. Nanomolar concen-
trations of DHEA or DHEAS promote the survival and dif-
ferentiation of cultured neurons (Bologa et al., 1987). Both
steroids also protected hippocampal neurons from the toxic
effects of glutamate (Cardounel et al., 1999) and stimulate
neurite growth in cultures of cortical neurons isolated from
embryonic rat brains by modulating the activity of NMDA
receptors (Compagnone and Mellon, 1998). When admin-
istered in vivo, DHEAS significantly attenuated learning
impairments induced by the administration of the NMDA
antagonist dizocilpine and of the muscarinic acetylcholine
receptor antagonist scopolamine (Maurice et al., 1997;
Urani et al., 1998). Treatment of adult rats with DHEA
has also recently been shown to stimulate the proliferation
of granule neurons within the hippocampal formation by
antagonizing the inhibitory effects of glucocorticosteroids
(Karishma and Herbert, 2002).
Particularly relevant to the aging process and AD may be
the observations that DHEA or DHEAS improve memory
performance in aging mice (Flood and Roberts, 1988), and
that PREG, DHEA and their sulfate esters protect against
-amyloid peptide-induced neurotoxicity and amnesia
(Cardounel et al., 1999; Maurice et al., 1998).
3. Steroidal aging in humans
The blood levels of specific gonadal and adrenal steroids
continuously decrease with age. In women, the abrupt de-
crease in ovarian estradiol and PROG at the time of the
menopause leads to a series of physical and emotional
symptoms and increased risk of cardiovascular diseases, os-
teoporosis and dementia, in particular of AD (Khaw, 1992;
Sowers and La Pietra, 1995; Wise et al., 1999; Burger et al.,
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2002). Measures of estrogen levels in women with AD
have provided conflicting results. Some studies have not
shown significant differences between healthy women and
women with AD (Cunningham et al., 2001). On the con-
trary, other studies have found decreased levels of estradiol
in AD patients (Manly et al., 2000). One study has reported
decreased estradiol levels in the cerebrospinal fluid of AD
patients and a negative correlation with -amyloid levels
(Schonknecht et al., 2001).
Circulating levels of PROG do not significantly change
with age in men (Vermeulen and Verdonck, 1976; Belanger
et al., 1994). That is, circulating PROG is exclusively of
adrenal origin in men and its production can be stimulated
by the administration of ACTH and inhibited by dexam-
ethasone, a synthetic glucocorticoid that exerts suppressive
effects on pituitary and adrenal activity (Gutai et al., 1977).
However, plasma levels of the GABAA receptor-active
PROG metabolite 3,5-TH PROG significantly decease
after the age of 40 years in men, whereas they remain
almost constant in women between the age of 20 and 70
years (Genazzani et al., 2002).
The decrease in testosterone production by the testes is
progressive, and in men, there is no state analogous to the
menopause. Total serum testosterone decreases by about
30% and free testosterone by as much as 50% between age
25 and 75 years (Vermeulen, 1991; Morley et al., 1997b). As
testosterone is an anabolic steroid, reduced androgen levels
with age lead to decreased muscle strength and bone mass
(van den Beld and Lamberts, 2002). In a cross-sectional
survey of healthy males, bioavailable testosterone corre-
lated negatively with age and in comparison with other
steroids correlated best with cognitive and physical mea-
sures (Morley et al., 1997a).
Circulating testosterone not only decreases in men with
progressing age, but also in women, as a consequence of
the age-dependent decline in ovarian and adrenal androgen
production. The mid-cycle rise in free testosterone and an-
drostenedione seen in younger women (19–37 years old)
is consistently absent in older women (43–47 years old;
Mushayandebvu et al., 1996). The 24 h mean plasma con-
centrations of total and of free testosterone also show a steep
diminution with age in healthy women between 21 and 51
years of age (Zumoff et al., 1995). The decrease in free
testosterone observed in older women can be further am-
plified by estrogen replacement therapy (ERT) because of
the suppression of the pituitary–gonadal axis (Mathur et al.,
1985).
The levels of two very abundant adrenal steroids, DHEA
and DHEAS, show a marked gradual reduction with pro-
gressing age in both men and women (Orentreich et al.,
1984; Ravaglia et al., 1996; Labrie et al., 1997b; Nafziger
et al., 1998; Laughlin and Barrett-Connor, 2000; Mazat
et al., 2001). Whether there is a link between reduced levels
of DHEA or DHEAS and AD is still a controversial issue.
Most studies have not found differences in DHEAS levels
between AD patients and non-demented patients (Legrain
et al., 1995; Yanase et al., 1996; Carlson et al., 1999;
Ferrario et al., 1999), whereas two studies have reported
decreased levels of DHEAS in AD patients (Leblhuber
et al., 1993; Murialdo et al., 2000). No apparent relation-
ship between circulating levels of DHEAS and cognitive
performance in the elderly has been found (Barrett-Connor
and Edelstein, 1994; Carlson and Sherwin, 1999; Kalmijn
et al., 1998; Mazat et al., 2001; Yaffe et al., 1998a). A sig-
nificant decrease in plasma PREG and PREGS also occurs
in men and women. This was shown in 56 healthy males,
ranging in age from 20 to 84 years (Morley et al., 1997a).
In contrast to most steroids, the adrenal production of glu-
cocorticoids is maintained throughout life (Herbert, 1995).
However, the brain may become more sensitive to circulating
cortisol with progressing age because of the marked decrease
in DHEA, which acts as an antiglucocorticoid (Kimonides
et al., 1999; McIntosh et al., 1993). Increased levels of cor-
tisol may represent a risk factor for the development of neu-
rodegenerative diseases (McEwen et al., 1999; Nichols et al.,
2001). Brain imaging techniques have allowed to show that
aging subjects with increased cortisol levels show a reduc-
tion in hippocampal volume and decreased attention and
memory performance. Whether these changes predict the
development of dementia or whether they are reversible is
unknown (Lupien et al., 1998, 1999).
4. Steroids in the aging nervous system: the endocrine
glands and local synthesis
Steroid hormones synthesized by the gonads and adrenal
glands easily cross the blood–brain and the blood–nerve bar-
riers and rapidly accumulate within the nervous tissues, ex-
cept for their conjugated forms such as the steroid sulfates,
which not easily enter the brain (see Wang et al., 1997). In
addition, as already mentioned above, neurosteroids can be
synthesized within the CNS and PNS by neurons and glial
cells (Robel et al., 1999; Baulieu et al., 2001). To qualify as
a neurosteroid, there are two requirements: (1) persistence
of the steroid in the nervous system in the absence of the
steroidogenic endocrine glands (gonads and adrenal glands);
and (2) expression and activity of the enzymes involved in
their synthesis. The work that has established the biosyn-
thetic pathways of neurosteroids in the nervous system of
experimental animals has already been extensively reviewed
(Robel et al., 1999; Mensah-Nyagan et al., 1999; Tsutsui
et al., 2000; Mellon et al., 2001; Mellon and Vaudry, 2001),
and this review will focus on neurosteroid biosynthesis and
metabolism in the human nervous system.
As both the endocrine glands and the local production
contribute to the pool of steroids present in the nervous
tissues, the age-dependent changes in circulating levels of
steroid hormones, which have been described in Section 3
on steroidal aging, not necessarily reflect changes in brain
levels. Whether the synthesis of neurosteroids changes with
age and plays a role in the aging process, eventually by
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compensating for the age-dependent decrease in circulating
hormones, needs to be explored. That is, the question of
the biological significance of neurosteroid synthesis in the
brain and in peripheral nerves has so far been directly ad-
dressed only by a few studies. Thus, there is evidence that
the local synthesis of PROG in peripheral nerves may play
a role in myelination: (1) Schwann cells convert PREG to
PROG and express the 3-hydroxysteroid dehydrogenase
(3-HSD), the enzyme involved in this reaction, in response
to a neuronal signal (Robert et al., 2001); (2) after cryole-
sion of the mouse sciatic nerve, blocking either the local
synthesis or the local activity of PROG during the process of
regeneration strongly inhibits the formation of new myelin
sheaths (Koenig et al., 1995); and (3) in DRG explant cul-
tures, mRNA levels of enzymes involved in the de novo
synthesis of PROG, namely the cytochrome P450scc (en-
zyme that converts cholesterol to PREG) and the 3-HSD,
are markedly increased during the peak of myelin formation
(Chan et al., 1998).
Results of another study suggest that the formation of
conjugated PREG within the hippocampus, a brain region
critically involved in spatial memory, may play an impor-
tant role in memory processes and in the aging of cognitive
performances. Levels of conjugated PREG were found to
be selectively reduced in the hippocampus in 2-year-old rats
with memory deficits. Most importantly, the memory deficits
of cognitively impaired aged rats could be transiently cor-
rected by intrahippocampal injection of PREGS. This study
strongly suggests that the local synthesis of neurosteroids
within distinct brain regions may be necessary for the main-
tenance of cognitive functions during aging (Vallée et al.,
1997).
The contribution of endogenous neurosteroids to the anti-
amnesic effects of 1 receptor agonists has been examined
in mice deprived of their steroidogenic endocrine glands
by castration and adrenalectomy to avoid the confusing ef-
fects of circulating steroids. Blocking the local synthesis of
PROG in the brain increased (+)-[3H]SKF-10047 binding
to 1 receptors and facilitated the antiamnesic effects of the
1 receptor agonist PRE-084, whereas increasing the accu-
mulation of locally synthesized PROG decreased 1 recep-
tor binding and prevented the PRE-084 effect (Phan et al.,
1999).
Local aromatization of circulating androgens to estradiol
in the brain plays an important role during regeneration. It
has recently been shown that expression of the aromatase, an
enzyme that converts androgens to estrogens, is induced in
reactive astrocytes near the lesion site (Garcia-Segura et al.,
1999) and that locally formed estradiol promotes the via-
bility of neurons in synergy with the peptide growth fac-
tor IGF-1 (Cardona-Gomez et al., 2001). Whether estradiol
formed in the brain form circulating testosterone can be
considered as a neurosteroid is a question of definition. Ini-
tially, the term “neurosteroid” referred to such steroids that
either are or can be synthesized de novo from cholesterol
within the nervous system (Baulieu, 1991). However, in the
literature, the term “neurosteroid” is also frequently applied
to steroid metabolites that are formed from circulating hor-
mones within the brain such as estradiol. The problem is
that these metabolites, in contrast to de novo synthesized
steroids, disappear from the nervous tissues after chirurgi-
cal removal of the steroidogenic endocrine glands. That is,
persistence in the brain after castration and adrenalectomy
was initially proposed as a criterion for the identification of
a neurosteroid (Corpéchot et al., 1981; Baulieu, 1991). An-
other term that is regularly used in a broader sense is the one
of “neuroactive steroid”. Initially, this term was proposed
for all natural or synthetic steroids that can rapidly alter
the excitability of neurons by binding to membrane-bound
receptors such as those for inhibitory or excitatory neuro-
transmitters (Paul and Purdy, 1992). However, it is now fre-
quently used to designate steroids with biological activity in
the nervous system.
Over the past years, evidence has accumulated that neu-
rosteroids may also be synthesized and metabolized in
the human nervous system (the metabolic pathways of
steroids are presented in Figs. 1 and 2). The mitochondrial
cytochrome P450scc, which catalyzes the conversion of
cholesterol to PREG, was first found in the human brain by
immunocytochemistry (Le Goascogne et al., 1989). Several
studies have described the presence of P450scc mRNA in
different regions of the human brain. In the hippocampus
of patients with temporal lobe epilepsy, P450scc mRNA
has been quantified by competitive RT-PCR. Its levels
were about 200 times lower than in the adrenal gland and
were higher in the hippocampus of women than of men
(Beyenburg et al., 1999; Watzka et al., 1999). In another
study, the mRNAs of the P450scc and of the steroid acute
regulatory protein (StAR), which plays a critical role in the
intramitochondrial transport of cholesterol and steroid syn-
thesis, have been detected by RT-PCR in the cerebral cortex
pons, cerebellum and hippocampus of men and women
(Inoue et al., 2002). The presence of P450scc mRNA
has also been detected by real-time RT-PCR in human
amygdala, caudate nucleus, cerebellum, corpus callosum,
hippocampus, spinal cord and thalamus (Yu et al., 2002).
Activity of the P450scc has so far not been reported for
human brain tissue, but has recently been examined in hu-
man brain cell lines with characteristics of either oligoden-
drocytes (myelin basic protein expression), astrocytes (glial
fibrillary acidic protein expression) or neurons (neurofila-
ment expression). Oligodendrocytes, but not astrocytes and
neurons, converted tritiated precursors to PREG. The cells
also expressed P450scc and mitochondrial benzodiazepine
receptor (MBR, also called peripheral benzodiazepine recep-
tor) mRNA and protein (Brown et al., 2000). Like the StAR
protein, the MBR is involved in the transport of cholesterol
into the mitochondria and agonists of this receptor have been
shown to increase the synthesis of steroids (Culty et al.,
1999; Stocco, 2001).
PREG is then converted to PROG by the 3-HSD. This
enzyme can use many 3-hydroxysteroids as substrates and
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Fig. 1. Biosynthetic pathways of steroids. Conversion of cholesterol to pregnenolone is catalyzed by the cytochrome P450scc (1) (scc: side chain cleav-
age). The other enzymes involved in steroid metabolism are: (2) 3-hydroxysteroid dehydrogenase (3-HSD); (3) cytochrome P450c21 (21-hydroxylase);
(4) cytochrome P45011 (11-hydroxylase); (5) 20-hydroxysteroid oxidoreductase; (6) cytochrome P450c17 (17-hydroxylase/17,20-lyase); (7)
17-hydroxysteroid oxidoreductases (17-HOR); (8) aromatase.
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Fig. 2. Reductive metabolic pathways of progesterone (a) and testosterone (b). Enzymes involved: (1) 5-reductase; (2) 5-reductase; (3) 3-hydroxysteroid
oxidoreductase (3-HOR); (4) 3-hydroxysteroid oxidoreductase (3-HOR).
also converts DHEA to androstenedione. The full name of
the enzyme is 3-hydroxysteroid dehydrogenase/5–4
isomerase, because it catalyzes two reactions on separate ac-
tive sites, located on a single protein: the dehydrogenation of
3-hydroxysteroids (3-HSD activity) and the subsequent
isomerization of 5-3-ketosteroids (double bond between
C5 and C6) to 4-3-ketosteroids (double bond between C4
and C5; ketosteroid isomerase (KSI) activity). The cDNAs
of two human isoforms (types I and II) have been isolated,
respectively, from placenta and adrenal glands and the cor-
responding genes, located on chromosome 1, have been
cloned (Lachance et al., 1990, 1991). Mutations in the type
II gene, which is predominantly expressed in the adrenal
glands and gonads, have been related to different forms
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of congenital adrenal hyperplasia associated with pseudo-
hermaphroditism (Simard et al., 1995). Yu et al. (2002) have
quantified 3-HSD mRNA by real-time RT-PCR in the
human amygdala, caudate nucleus, cerebellum, corpus cal-
losum, hippocampus, spinal cord and thalamus. The primers
used in their study did not allow to distinguish between the
type I and II isoforms. The 3-HSD mRNA was present in
all brain regions examined and highest levels were found in
the myelin-rich corpus callosum and in the spinal cord (Yu
et al., 2002). Both 3-HSD and PR mRNA were found to
be present within distinct regions, suggesting local synthe-
sis and autocrine/paracrine actions of PROG in the human
brain (Inoue et al., 2002). Cultured human oligodendroglial,
astroglial and neuronal cell lines all expressed the 3-HSD
(Brown et al., 2000). The observation that human glioma
cells with an oligodendroglial phenotype (expressing the
myelin basic protein) express both P450scc and 3-HSD
suggests that human oligodendrocytes may have the capac-
ity to synthesize PROG de novo from cholesterol (Brown
et al., 2000).
PREG can also be converted to DHEA and PROG to an-
drostenedione by the cytochrome P450c17 (17-hydroxylase/
17,20-lyase). P450c17 mRNA has been detected by real-time
PCR in different regions of the human brain (Yu et al.,
2002). Although one study has failed to demonstrate
P450c17 activity in human brain cell lines (Brown et al.,
2000), it is very likely that the enzyme expressed in human
brain is functional. In fact, brain P450c17 activity appears
to be conserved through the vertebrate phylum and has
been demonstrated in amphibians (Mensah-Nyagan et al.,
1999), birds (Matsunaga et al., 2001) and rodents (Zwain
and Yen, 1999a,b). An alternative mechanism of DHEA
formation has been observed in human glial cells. In these
cells, DHEA may be synthesized through a cytochrome
P450c17-independent and Fe2+-dependent pathway as has
been previously described for cultured rat oligodendrocytes
and astrocytes (Cascio et al., 2000). Thus, the treatment of
human oligodendrocytes and astrocytes, but not neurons,
with FeSO4, induced the formation of DHEA. The synthe-
sis of DHEA could not be blocked by the P450c17 inhibitor
SU 10603, indicating that the enzyme was not involved.
Interestingly, the treatment of human oligodendrocytes
with -amyloid peptides, which increased the formation
of reactive oxygen species (ROS), also increased DHEA
formation (Brown et al., 2000). This observation suggests
that the local synthesis of DHEA by glial cells in response
to ROS and -amyloid peptides may play an important role
in neuronal survival.
DHEA is further converted to a series of metabo-
lites and these metabolic pathways are likely to reg-
ulate its levels and activity in the brain. As already
mentioned, the 3-HSD converts DHEA to the andro-
gen androstenedione. The 17-hydroxysteroid oxidore-
ductases (17-HORs, also called 17-hydroxysteroid
dehydrogenase), which catalyze the final steps of an-
drogen and estrogen biosynthesis (androstenedione ↔
Fig. 3. Metabolism of dehydroepiandrosterone to 5-androstene-
3,17-diol by the 17-hydroxysteroid oxidoreductases and to 7-OH-
dehydroepiandrosterone by the 7-hydroxylase (P450c7), as it occurs in
the aging brain from Alzheimer’s patients and non-demented controls
(modified from Weill-Engerer et al., 2003).
testosterone and estrone ↔ estradiol), also convert DHEA
to 5-androstene-3,17-diol (ADIOL). The mRNAs en-
coding the 17-HORs isozymes 1, 3, 4 and 5 have also been
detected and quantified in human brain and their respec-
tive levels showed no significant differences between men
and women (Steckelbroeck et al., 2001b; Beyenburg et al.,
2000). 17-HOR activity has been demonstrated in human
fetal brain, in meningiomas (Knapstein et al., 1968; Jenkins
and Hall, 1977; Carlson et al., 1994) and in temporal lobe
biopsies from men and women suffering from epilepsy,
and again, no sex differences were observed (Steckelbroeck
et al., 1999b). When human SH-SY5Y neuroblastoma cells
are incubated with testosterone, they form large amounts
of androstenedione, indicative of catalysis by highly active
17-HOR (Wozniak et al., 1998).
In addition to its conversion to ADIOL by the 17-HORs,
DHEA is also converted by a 7-hydroxylase (P450c7) to
7-OH-DHEA. The activity of this enzyme has recently
been demonstrated in the human brain of both sexes. It is
significantly higher in the cerebral cortex than in the subcor-
tical white matter from biopsies (Steckelbroeck et al., 2002).
The biological significance of 7-OH-DHEA and ADIOL
in the brain still needs to be elucidated. In peripheral tissues,
both metabolites have been found to up-regulate immunity
and to counteract immunosuppression (Padgett and Loria,
1994; Hampl et al., 1997; Morfin et al., 2000; Lathe, 2002;
Loria, 2002).
The metabolism of DHEA to ADIOL and to 7-OH-
DHEA has recently been studied for the first time in the
aging brain from AD patients and non-demented controls
(age: 75–91 years; Weill-Engerer et al., 2003) (Fig. 3). The
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formation of these metabolites occurred in frontal cortex,
hippocampus, amygdala, cerebellum and striatum of both
AD patients and controls. Regional differences were ob-
served in the two groups, with significantly higher formation
of 7-OH-DHEA in the frontal cortex compared to other
brain regions, and of ADIOL in cerebellum and striatum
compared to frontal cortex. Interestingly, a trend toward a
negative correlation was found between the density of cor-
tical -amyloid deposits and the amount of 7-OH-DHEA
formed in the frontal cortex and that of ADIOL formed in
the hippocampus (Weill-Engerer et al., 2003).
The enzymes involved in the metabolism of PROG and of
testosterone were found to be expressed in the human brain.
Levels of different mRNAs encoding the 5-reductase 1, the
3-hydroxysteroid oxidoreductases (3-HORs) 2 and 3 and
the 20-hydroxysteroid dehydrogenase have been quanti-
fied by real-time RT-PCR in the hippocampus and temporal
lobe cortex from patients with pharmacoresistant tempo-
ral lobe epilepsy. Interestingly, plasma levels of 3,5-TH
PROG did not correlate with mRNA expression levels
of the enzymes involved in its synthesis (Stoffel-Wagner
et al., 2003). In this study, the 3-HOR was referred to
as 3-hydroxysteroid dehydrogenase (3-HSD). In this re-
view, we use the term 3-HOR according to the recently
suggested nomenclature of enzymes involved in steroid
metabolism (Baulieu et al., 1999), because the reaction
catalyzed by the enzyme is reversible.
The enzymatic activity of the 5-reductase has first been
demonstrated in human brain tissues by using either PROG
or testosterone as substrates (Jenkins and Hall, 1977; Saitoh
et al., 1982). The enzymatic activities of the 5-reductase
and the 3-HOR were found to colocalize at all life stages
in the cerebral cortex and subcortical white matter of both
men and women, but no sex-specific differences in enzyme
activities were observed (Steckelbroeck et al., 2001a). The
human neuroblastoma cells SH-SY5Y actively metabo-
lize PROG and testosterone to their respective 5-reduced
metabolites. Differentiation of the neuroblastoma cells is
paralleled by a significant increase in the expression of
the 5-reductase 1 and of the formation of 5-reduced
steroid metabolites (Maggi et al., 1998). When homogenates
from human male and female frontal cortex were incu-
bated with testosterone, not only 5-dihydrotestosterone
but also 5-dihydrotestosterone was formed in significant
amounts (Wozniak et al., 1998). It has been proposed that
5-reduction of steroids may correspond to an inactivation
pathway, thus regulating the amount of substrate avail-
able for the formation of biologically active metabolites
(Hutchison and Steimer, 1981; Steimer and Hutchison,
1981). In addition, 5-reduced metabolites of testosterone
may directly inhibit the activity of enzymes, such as the
aromatase, involved in the formation of neuroactive steroids
(Schumacher et al., 1991).
An interesting question is whether the human brain
has the potential for glucocorticoid synthesis, because
the mRNAs for all the enzymes required for the synthe-
sis of cortisol from cholesterol have been detected. The
cytochrome P45021 converts PROG and 17-OH-PROG
to 11-deoxycorticosterone and 11-deoxycortisol. Humans
have two P45021 genes, one of which is an inactive pseu-
dogene (White et al., 1985). In an early study, the activity
of the enzyme was demonstrated in human fetal brain,
but its mRNA was not detected by solution hybridization
(Mellon and Miller, 1989). More recently, very low levels
of cytochrome P45021 mRNA have been detected in the hu-
man hippocampus, at levels about 10,000 times lower than
those measured in adrenal gland tissue (Beyenburg et al.,
2001). Transcripts of the cytochromes P45021 and P45011,
which catalyze the final steps in the synthesis of gluco-
corticoids (11-deoxycorticosterone → corticosterone and
11-deoxycortisol → cortisol), have also been measured in
different regions of the human brain by real-time RT-PCR.
Cytochrome P45021 was expressed in the amygdala, caudate
nucleus, cerebellum, corpus callosum, hippocampus, thala-
mus and spinal cord and cytochrome P45011 in all these
regions, except in the cerebellum and hippocampus. De-
pending on the brain region, mRNA levels were 100–10,000
times less than in the adrenal gland (Yu et al., 2002).
The activity of the aromatase, the enzyme that converts
androgens to estrogens, has been characterized in micro-
somal preparations of temporal lobe biopsies as well as
in cerebral cortex and subcortical white matter samples of
adults and children with epilepsy. Aromatase activity was
found to be higher in cerebral cortex than in white mat-
ter, but no differences were observed between sexes or ages
(Steckelbroeck et al., 1999a). Another study has examined
aromatase activity in the human neuroblastoma cell line
SH-SY5Y and in human postmortem brain samples of AD
and control patients. The aromatase activity in differenti-
ated neuroblastoma cells was lower than in undifferentiated
cells. Homogenates of adult human male and female cortex
and frontal and temporal areas of both AD and control pa-
tients all showed considerably lower enzyme activity than
the neuroblastoma cells. The temporal cortical area had sig-
nificantly higher aromatase activity than the frontal one. No
significant difference in aromatase activity was observed be-
tween control and AD brains (Wozniak et al., 1998).
5. Levels of steroids in the human nervous system
Because steroids can be synthesized within the nervous
system and because they may differently accumulate within
distinct compartments of the nervous system, their blood
levels do not necessarily reflect their concentrations and
bioavailability in the brain and in peripheral nerves. Only
a few studies have investigated the distribution of neuros-
teroid concentrations in human brain by radioimmunoassay
(RIA; Lanthier and Patwardhan, 1986; Lacroix et al., 1987;
Hammond et al., 1983; Bixo et al., 1997). Measurements
of neurosteroids in postmortem human brains are associ-
ated with great difficulties, and they need to be cautiously
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interpreted because material is obtained by autopsy, and the
conditions of death, tissue sampling and storage cannot be
subject to the same degree of control as in animal experi-
ments. The delay from death to storage is generally as long
as 24–48 h, which may significantly affect the brain content
of steroids and of their metabolites. Recently, it has been
reported that cells in slices from adult human postmortem
brain can survive for extensive periods (Verwer et al., 2000).
The endocrinological and neurological status of the patients
need to be taken into account.
The data of two studies indicate that PREG and DHEA
are the most abundant steroids in the human brain, values
for PREG being greater than those for DHEA (Lanthier and
Patwardhan, 1986; Lacroix et al., 1987). They also show that
high levels of steroids are still present in the brains of aged
patients. In the study of Lanthier and Patwardhan (1986),
based on three men and two women (age: 56–75 years), no
marked differences in the concentrations of PREG, DHEA,
PROG, androstenedione, testosterone, estradiol and estrone
were observed between different brain regions, including the
hypothalamus, amygdala, hippocampus and different parts
of the cerebral cortex. The small number of samples did
not indicate sex differences in brain steroid levels, except
for somewhat higher DHEA levels in the two women. In
the study of Lacroix et al. (1987), based on nine women
and one man (age: 76–93 years), levels of PREG, PROG,
17-OH-PROG, androstenedione and DHEA varied little
among different brain regions, including the cerebral cortex,
cerebellum and corpus callosum. The concentrations of these
steroids were seven to nine times higher in brain tissue when
compared to plasma, suggesting their accumulation or local
synthesis in the brain.
In another study, the concentrations of PROG, androstene-
dione, testosterone, 5-dihydrotestosterone and andros-
terone have been measured in different brain regions of four
male (age: 2.5–58 years) and four female (age: 4–82 years)
cadavers (Hammond et al., 1983). Because of the limited
number of samples and the wide range of ages, it is diffi-
cult to draw firm conclusions from this work. In the adult
brains, no differences were observed for the concentrations
of steroids between different regions (amygdala, hypothala-
mus, parietal cortex) and between sexes, with the exception
of higher testosterone levels in men as compared to women.
In a more recent study, levels of PROG, 5-dihydropro-
gesterone and 3,5-TH PROG were measured in distinct
brain regions and in plasma of five fertile women (age:
18–42 years) and of five menopausal women (age: 59–85
years; Bixo et al., 1997). Brain concentrations of these three
steroids were higher in fertile women in their luteal phase
compared to the postmenopausal women and were partially
depending on ovarian steroid production, indicating that
serum levels determine the uptake of progestins by the brain.
In spite of the correlation between blood and brain levels of
PROG, it is important to note that in women with low serum
concentrations of PROG, brain concentrations of PROG and
of its 5-reduced metabolites were elevated, suggesting ac-
cumulation or local formation. In addition, significant differ-
ences of steroid levels between brain regions were observed
in this study, suggesting the existence of local regulatory
mechanisms such as accumulation, synthesis or metabolism
(Bixo et al., 1997). Postmortem concentrations of estradiol
and testosterone have also been measured in 17 brain ar-
eas and serum of 6 fertile and 5 postmenopausal women.
There were regional differences in the brain concentrations
of both steroids, with highest levels of estradiol and testos-
terone in the hypothalamus, preoptic area and substantia
nigra. Estradiol concentrations were significantly higher in
the blood and in specific brain regions (preoptic area and
substantia nigra) of fertile women when compared to post-
menopausal women. Differences between fertile and post-
menopausal women were not significant for testosterone.
Brain levels of this steroid were found to be rather stable
and did not vary with serum testosterone levels (Bixo et al.,
1995).
Total corticosteroid concentrations were found to be lower
in the brain than in plasma, but brain concentrations were
greater than the presumed unbound fraction in plasma. All
the brain regions examined contained approximately equal
amounts of corticosteroids (Carroll et al., 1975).
So far, only one study has examined steroid levels by RIA
in the brains of AD patients and in controls. In the control
brains, levels of estradiol were 3.5-fold higher in men than
in women and levels of testosterone were equivalent (age of
men: 73±9 years; age of women: 79±11 years). There were
no significant differences in brain steroid levels between
control and AD patients (Twist et al., 2000).
As in the brain, very high levels of PREG have also been
measured in human sciatic nerves, consistent with its local
synthesis by Schwann cells. Its mean concentration (64 ±
46 ng/g) was about two orders of magnitude higher than
levels in blood, tendons and muscle. No correlation was
found with sex or age (Morfin et al., 1992).
6. Analysis of steroids by gas chromatography/mass
spectrometry (GC/MS)
Results described in Sections 4 and 5 are based on the as-
say of steroids in plasma and brain tissue by RIA (Abraham,
1975; Carroll et al., 1975; Buster and Abraham, 1975).
Although this method has allowed considerable progress
in endocrine research, it has considerable limits with re-
spect to specificity and sensitivity, and it is dependent on
the availability of antisera. This is particularly problematic
for neuroendocrine research, which requires the analysis of
low levels of several steroids within individual small tissue
samples. The development of very sensitive and precise
analysis of steroids by GC/MS has represented a major
breakthrough in this regard. In fact, because of its sensitiv-
ity in the femtomolar range, this method allows to analyze
small amounts of neurosteroids in nervous tissues with
great precision and reproducibility. Already introduced in
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the 1970s, analysis of steroids by GC/MS has been con-
siderably improved since then. The work of the groups of
Lieberman (Mathur et al., 1993; Prasad et al., 1985) and
of Guidotti (Cheney et al., 1995) has demonstrated that the
GC/MS technology can be used to measure sub-picomolar
concentrations of neurosteroids in brain tissue.
More recently, the different steps of the assay have been
optimized to improve its sensitivity and to allow the simul-
taneous measure of a large range of free and conjugated
neurosteroids within distinct brain regions (Liere et al.,
2000). The high sensitivity and robustness of the assay rely
in part on the appropriate purification and separation of
the biological extracts by solid phase extraction (SPE) on
C18 columns and by high performance liquid chromatog-

































Fig. 4. Analytical procedure for the analysis of the unconjugated steroids (free steroids) and conjugated steroids (sulfates and lipoidal derivatives) in
blood and brain tissue by GC/MS (SPE: solid phase extraction) For a more detailed description, see Section 6.
steroids according to their physico-chemical characteris-
tics (Fig. 4). The current protocol allows to detect and
to quantify steroids of different polarities, ranging from
hydrophilic steroid sulfates to lipophilic steroids, in a sin-
gle tissue sample of a few milligrams. The separation of
the different types of free steroids by HPLC also allows
their optimal derivatization and the simultaneous analysis
of 3-ceto as well as of 3-ceto-4 mono-and polyhydrox-
ylated steroids in a same tissue sample. That is, prior to
their separation by GC and their analysis by MS, steroids
are converted to halogenous or silylated derivatives. The
derivatization of the steroid molecules increases their
volatility, thus allowing a good chromatographic resolution,
and also improves the detection of specific diagnostic ions
(i.e. with high molecular mass) in the mass spectrum. The
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derivatization reactions thus lead to increased sensitivity of
the assay.
After their derivatization, steroids can be analyzed by op-
erating the mass spectrometer either in the negative chem-
ical ionization mode (NCI; Uzunov et al., 1996) or in the
electronic impact mode (EI; Cheney et al., 1995; Liere et al.,
2000). In the NCI mode, the impact of electrons (e−, 150 eV)
with methane molecules (CH4) produces low energy ther-
mic electrons (e−th), characterized by a kinetic energy less
than 1 eV, which react with the halogenous steroid deriva-
tives (M). This gentle ionization procedure produces little
fragmentation of the steroid molecules:
CH4 + e− → CH4•+ + 2e−th
M+ e−th → M•−
In the robust EI ionization mode, the impact of e− (70 eV)
with the steroid derivative (M) produces ionized fragments
(F•+), which are characteristic of the steroid molecule to be
analyzed (N = neutral fragments, M•+∗ = unstable molec-
ular ion):
M+ e− → M•+∗ + 2e−
M•+∗ → F•+ + N
Fig. 5 illustrates the advantages of the GC/MS technology
for the simultaneous analysis of a range of steroids, com-
bining the high resolution and selectivity of the GC and the
reliability of identification of the MS. The mass spectra (pro-
files of ion fragments) correspond indeed to molecular fin-
gerprints of the steroid derivatives. However, not all steroid
derivatives are separated by the GC and some have a similar
mass spectrum. In fact, the power of the GC/MS analysis re-
sides in the bi-dimensional analysis of the steroid derivatives
by both GC and MS. This is illustrated in Fig. 5: the heptaflu-
orobutyrate derivatives (HFB) of the 3- and 3-isomers of
tetrahydroprogesterone (allopregnanolone and isoallopreg-
nanolone) have an identical mass spectrum, but they are well
separated by GC. In contrast, the HFB derivatives of PREG
and PROG are not separated by GC, but their distinct mass
spectra allow to identify and to quantify them separately.
7. Analysis of neurosteroids in the brains of aged
patients by GC/MS
Whether decreased levels of steroids contribute to the de-
velopment of dementia is still unclear. As described above,
measures of blood levels of DHEA and DHEAS in AD pa-
tients have provided conflicting results (Leblhuber et al.,
1993; Legrain et al., 1995; Yanase et al., 1996; Carlson et al.,
1999; Ferrario et al., 1999; Murialdo et al., 2000). A com-
parative analysis of the concentrations of several neuros-
teroids in various brain regions between aged AD patients
and aged non-demented controls has been recently reported
(Weill-Engerer et al., 2002). Neurosteroids measured by
GC/MS included PREG, PREGS, DHEA, DHEAS, PROG
and 3,5-TH PROG. The following six brain regions were
analyzed for their steroid content: hippocampus, amygdala,
frontal cortex, striatum, hypothalamus and cerebellum.
The non-demented control group comprised two women
and four men (age: 75–91 years) and the AD group four
women and one man (age: 81–91 years). Severe exclusion
criteria were applied in this study. The postmortem delay did
not exceed 24 h, and none of the patients received steroids
or benzodiazepines during the month before death. For neu-
rological characterization, dementia was considered using
the criteria of Diagnostic and Statistical Manual of Mental
Disorders and criteria of AD were those proposed by the
National Institute of Neurological and Communicative Dis-
orders and Stroke–Alzheimer’s Disease and Related Disor-
ders Association. At the time of autopsy, one hemisphere of
each brain was formalin-fixed for neuropathological exami-
nation, and the other one was deep-frozen until biochemical
measures were performed (Weill-Engerer et al., 2002).
This study is the first to use GC/MS technology to quan-
tify neurosteroids in the human brain and thus provides ref-
erence values. In agreement with previous studies using RIA
(see Section 5), PREG was the most abundant neurosteroid
in the different brain regions. Steroids found at the highest
concentrations were in decreasing order PREG > DHEA >
PROG > PREGS > DHEAS 	 3α, 5α-TH PROG. It is
important to note that levels of all these steroids, except
for 3,5-TH PROG, were found to be still elevated in the
brains of these old patients, and that they were much higher
than previously reported blood levels (Morley et al., 1997a;
Hill et al., 1999; Labrie et al., 1997a). Differences in steroid
levels were observed between brain regions in non-demented
patients, but not in AD patients. In addition to the disap-
pearance of regional differences, there was a general trend
toward lower levels of steroids in the six brain regions of AD
patients compared with the controls (Fig. 6) (Weill-Engerer
et al., 2002). A significant finding was the correlation be-
tween neurosteroid levels and two biochemical markers of
AD, namely, levels of phosphorylated tau proteins (PHF-tau)
and -amyloid peptides. PHF-tau levels were negatively cor-
related with DHEAS concentrations in the hypothalamus and
-amyloid peptide levels were negatively correlated with
PREGS levels and to some extent with DHEAS levels in the
striatum and cerebellum (Weill-Engerer et al., 2002).
8. Age-dependent changes in the nervous system
can be reversed by steroids
Data concerning changes in brain steroid levels with age
are still fragmentary and do not allow to draw definite con-
clusions concerning the role of steroids in the aging process
of the nervous system. Obviously, more studies are urgently
required. A related important question for the development
of hormone therapies is whether age-related dysfunctions of













Fig. 5. The GC/MS technology combines the high resolution and selectivity of the GC and the reliability of identification of the MS. The heptafluorobutyrate derivatives (HFB) of the 3- and 3-isomers
of tetrahydroprogesterone have an identical mass spectrum, but they are well separated by GC (a). The HFB derivatives of PREG (b) and PROG (c) are not separated by GC, but can be distinguished by
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Fig. 6. Concentrations of pregnenolone (PREG), dehydroepiandrosterone (DHEA), their sulfates (PREGS and DHEAS), progesterone (PROG), and
3,5-tetrahydroprogesterone (3,5-TH PROG: allopregnanolone) measured in six brain regions of non-demented (white columns) and Alzheimer’s
(black columns) patients by GC/MS. HC: hippocampus; A: amygdala; FC: frontal cortex; ST: striatum; HT: hypothalamus; C: cerebellum (∗P ≤ 0.05 by
Mann–Whitney test; modified from Weill-Engerer et al., 2002).
administration of steroids. We have already presented ev-
idence that age-dependent changes of the nervous system
are subtler than previously thought, and that the aging ner-
vous system maintains some capacity for regeneration. Sev-
eral recent experiments using aged animals have provided
evidence that the aging nervous system indeed retains sen-
sitivity to the trophic and protective effects of steroids and
that their administration allows to improve altered nervous
functions.
As already mentioned above, the spatial memory deficits
of cognitively impaired aged rats (2 years old) can be tran-
siently corrected by intrahippocampal injection of PREGS
(Vallée et al., 1997). In young female rats (3–4 months old),
the administration of low doses of estradiol attenuates is-
chemic brain injury. The protective actions of estradiol are
most prominent in the cerebral cortex. Middle-aged rats
(9–12 months old) remain equally responsive to the protec-
tive effects of estradiol after middle cerebral artery occlusion
(MCAO; Wise et al., 2001; Dubal and Wise, 2001).
The prolonged treatment with progestins also allows
to reverse age-related myelin abnormalities. It was first
shown that the treatment of aged rats for 1 month with
progestins reversed the age-dependent decline in periph-
eral myelin protein P0 expression, whereas the adminis-
tration of androgens was without effect (Melcangi et al.,
1998a,b). The prolonged administration of progestins
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(PROG, 5-dihydroprogesterone or 3,5-TH PROG) not
only counteracted the drop in P0 mRNA, it also allowed
to improve age-related structural abnormalities of the pe-
ripheral myelin sheaths. Androgens were again found to
be inefficient (Azcoitia et al., 2003). In the CNS of old
male rats, administration of PROG for 5 weeks promoted
the slow remyelination of axons by oligodendrocytes after
toxin-induced demyelination (Ibanez et al., in press).
9. Hormone replacement therapy in humans
To compensate for the age-dependent decline in circulat-
ing steroid levels, hormone replacement therapies are now
commonly used for promoting successful aging (Lamberts
et al., 1997). As estradiol has important functions in bones,
in the cardiovascular system and in the nervous system, es-
trogen replacement therapy in postmenopausal women has
elicited particular interest (Wise et al., 1999). A now stan-
dard practice is to give estrogens together with progestins to
reduce the risk of endometrial cancer (Sitruk-Ware, 2000).
With respect to the nervous system, many studies have
suggested that ERT may improve cognitive functions, may
protect against age-associated memory decline and may
delay the onset and decrease the risk of AD (Phillips and
Sherwin, 1992; Brenner et al., 1994; Paganini-Hill and
Henderson, 1994, 1996; Kawas et al., 1997; Jacobs et al.,
1998; Resnick et al., 1998; Costa et al., 1999; Smith et al.,
2001; Fillenbaum et al., 2001; Tang et al., 1996; Yaffe et al.,
1998b). Estrogens may not only protect against the onset of
AD, they may also maintain cognitive functions in women
who already have AD (Henderson et al., 1994; Asthana
et al., 1999, 2001). However, some studies have questioned
the positive impact of ERT on the risk of AD or on cognitive
decline in women with AD (Brenner et al., 1994; Henderson
et al., 2000; Mulnard et al., 2000; Wang et al., 2000).
A major controversy has been launched during the past
few months concerning the use of HRT in postmenopausal
women. Five studies recently published by the Women’s
Health Initiative (WHI), all based on the same large ran-
domized and controlled trial, have indeed seriously ques-
tioned the favorable effects of estrogen plus progestin
therapy in postmenopausal women and have pointed to
the risks (Women’s Health Initiative Investigators, 2002,
2003a,b,c,d). This huge trial investigated the effects of
the treatment with 0.625 mg per day of conjugated equine
estrogens plus 2.5 mg per day of the synthetic progestin
medroxyprogesterone acetate (E +MPA) on the incidence
of coronary heart disease, breast cancer, stroke, global
cognitive functions, MCI and dementia in postmenopausal
women with an intact uterus aged 50–79 years (8102 women
were enrolled in the placebo group and 8506 women in
the E +MPA group). The initially planned duration of the
trial was 8.5 years, but it was prematurely stopped after
only 5.2 years, because the overall health risks of the hor-
mone treatment outweighed the benefits (a parallel trial
of estrogen alone in women with hysterectomy is still in
progress). A first study based on the WHI trial reported that
the rate of coronary heart disease was slightly increased in
E +MPA women (3.7/1000 person-years) when compared
to the placebo group (3/1000 person-years; Women’s Health
Initiative Investigators, 2002). There was also a modest
increase in invasive breast cancer in E + MPA women
(3.8/1000 person-years versus 3/1000 person-years). A sec-
ond study of the WHI trial reported an increased risk of is-
chemic stroke in healthy postmenopausal women (Women’s
Health Initiative Investigators, 2003c). After an average
of 5.6 years of follow-up, there were 151 strokes in the
E +MPA group and 107 strokes in the placebo group. The
risk was similar for the younger women participating in the
trial (50–59 years old). The third WHI study reported that
estrogen plus progestin did not improve cognitive functions
in postmenopausal women 65 years or older, but that there
was a small risk for cognitive decline when compared with
placebo (Women’s Health Initiative Investigators, 2003b).
The fourth study showed that in postmenopausal women
aged 65 years or older, daily estrogen plus progestin after
an average 4 years of follow-up did not prevent MCI but
increased the risk of dementia, although the number of
women with dementia was small (4.5/1000 person-years
versus 2.2/1000 person-years; Women’s Health Initiative
Investigators, 2003a). This increased risk in dementia may
have resulted from the cardiovascular effects of the steroids,
as vascular diseases often coexist with dementia (Snowdon
et al., 1997; Yaffe, 2003).
Finally, a fifth study based on the WHI trial reported that
estrogen plus progestin had no significant effects on general
health, vitality, mental health, depressive symptoms or sex-
ual satisfaction. After 3 years of trial, no meaningful ben-
efits in terms of quality of life were observed (Women’s
Health Initiative Investigators, 2003d). Because of the lack
of favorable effects of the HRT and of the significantly in-
creased risk, the WHI recommended not to initiate or to
continue estrogen plus MPA replacement therapy in post-
menopausal women with an intact uterus for the prevention
of coronary heart disease, stroke and dementia. According
to their recommendations, hormone therapy should only be
prescribed for temporary use to treat menopausal symptoms
(Yaffe, 2003).
What may explain the discrepancies between the outcome
of this large trial and the wealth of animal studies and the
many previous clinical trials that supported beneficial and
protective effects of estrogens on the cardiovascular system
and on cognitive functions? Many questions remain open
after this trial with respect to the timing of the HRT, the doses
of steroids, the mode of their administration and the steroid
compounds used. Thus, the WHI study did not address the
effects of short-term HRT and of prolonged HRT starting
early during the perimenopausal period. The trial also did not
address the benefits of HRT for the treatment of menopausal
symptoms such as hot flashes. It is also important to note that
the absolute risks associated with the daily estrogen–MPA
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therapy were rather small and that the all-cause mortality
was not affected during the trial (Women’s Health Initiative
Investigators, 2002).
An important matter for discussion is the use of a rela-
tively high dose of conjugated equine estrogen in combina-
tion with the synthetic progestin MPA in the WHI trial. With
respect to the latter, controversy has been raised over the role
of progestins in HRT and their risks. There are in fact sev-
eral classes of progestins, which differ by their pharmaco-
logical properties. Natural PROG and some of its derivatives
such as the 19-norprogesterones (nestorone, nonmegestrol
acetate, trimegestone) do not have androgenic side effects.
Other newly synthesized progestins have partial antiandro-
genic properties, such as drospirenone, which is a derivative
of spironolactone and binds to the mineralocorticoid recep-
tor (Henzl and Edwards, 2000; Sitruk-Ware, 2002). Some of
the frequently used progestins bind to the androgen recep-
tor and have high androgenic potency and eventually may
attenuate the beneficial actions of estrogens or exert delete-
rious effects, which are not necessarily shared by progestins
devoid of androgenic properties.
MPA, which has been used in the WHI trial and is one of
the clinically most used progestins, has both androgenic and
synandrogenic properties (Bullock et al., 1978; Sitruk-Ware,
2002). MPA has also been reported to possess glucocorti-
coid activity (Ishida et al., 2002) and to inhibit the beneficial
effects of estrogen (Wakatsuki et al., 2001). In addition, pro-
longed MPA treatment affects other endocrine responses in
postmenopausal women: it decreases LH and FSH and in-
creases IGF-1 levels (Saaresranta et al., 2002). These inter-
actions of MPA with other hormone signaling systems may
account for some of its side effects on the cardiovascular
and nervous systems that are listed further.
Concerning the cardiovascular system, a study in rhe-
sus monkeys has shown that estradiol plus PROG protects
against coronary vasospasm, but that estradiol plus MPA
failed to protect, suggesting that MPA may increase the
risk of this affection (Miyagawa et al., 1997). Other studies
confirm that MPA blunts the beneficial effects of estrogen
and that this synthetic progestin does not exert the same
effects as natural PROG. In postmenopausal women, MPA
has been shown to inhibit the beneficial effects of estro-
gen on endothelium-dependent vasodilatation (Wakatsuki
et al., 2001; Kawano et al., 2001). Natural PROG, but
not MPA, enhanced the beneficial effects of estrogen on
exercise-induced myocardial ischemia (Rosano et al., 2000).
MPA, but not micronized PROG, blunted the beneficial
association between estrogen and high-density lipoprotein
(HDL) cholesterol (Barrett-Connor et al., 1997). However,
the increase in cerebrovascular endothelial nitric oxide syn-
thase (eNOS) activity by estradiol, which corresponds to
one of its vasoprotective mechanisms of action (Chen et al.,
1999), was not prevented by the concurrent administration
of MPA (McNeill et al., 2002).
With respect to the nervous system, estradiol, PROG or
19-norprogesterone, alone or in combination, protect hip-
pocampal neurons against glutamate cytotoxicity. Not only
was MPA ineffective in protecting the neurons, this com-
pound also inhibited the neuroprotective effects of estradiol
when coadministered. In agreement with this observation,
estradiol, PROG or 19-norprogesterone all increased expres-
sion of the antiapoptotic protein B-cell leukemia/lymphoma
(Bcl-2), whereas MPA blocked estrogen-induced Bcl-2
expression (Nilsen and Brinton, 2002). Continuous MPA
users more likely reported depressive symptoms than con-
trols (Civic et al., 2000; Saaresranta et al., 2002). MPA also
opposes the beneficial association between estrogen and
cognitive changes (Rice et al., 2000). However, a recent
study has reported beneficial effects of MPA on mood in
postmenopausal women, and in particular in those with a
history of premenstrual syndrome (Bjorn et al., 2002).
The decline in testosterone levels in men with age is
very progressive and shows great inter-individual variability.
The clinical manifestations of androgen deficiency in men
may include decreased muscle mass and strength, increased
fat mass, decreased hematocrit, decreased libido, erectile
dysfunction, infertility, osteoporosis, anxiety, irritability, in-
somnia, depressed mood. Androgen replacement therapy
with testosterone has been proposed to be a safe and effec-
tive treatment for testosterone deficiency (Sternbach, 1998;
Winters, 1999). However, there are only a limited number
of testosterone replacement studies with sometimes conflict-
ing results (Sih et al., 1997; Tenover, 1992; Snyder et al.,
1999a,b). In particular, in hypogonadal men, testosterone
therapy may offer benefit, but long-term studies on its ef-
ficacy and safety are still lacking. One study has reported
that testosterone replacement therapy may improve depres-
sion and promote verbal and spatial memory in aging men
(Sternbach, 1998). Supplementation of healthy older men
with testosterone for 3 months enhanced their spatial cog-
nition, but did not significantly influence verbal and visual
memory, cognitive flexibility and mood (Janowsky et al.,
1994).
As testosterone also significantly declines after meno-
pause, restoring its levels may also be of benefit for women
and improve their quality of life with respect to libido, sense
of well-being, protection of cardiovascular health and pre-
vention of osteoporosis (Rako, 1998). Inclusion of testos-
terone in postmenopausal HRT is not uncommon, and andro-
gen therapy has been shown to alleviate several symptoms in
postmenopausal women and to improve their quality of life.
Whether the therapeutic effects of testosterone replacement
are mediated by testosterone itself, its 5-reduced metabo-
lites or are a consequence of its aromatization to estrogen is
unknown (Davis, 1999).
Placebo-controlled studies have also documented ben-
eficial effects of the oral administration of DHEA in the
elderly. Daily treatment with DHEA of men and women of
advancing age resulted in an increase in perceived phys-
ical and psychological well-being, increased lean body
mass in both sexes and increased muscle strength in men
(Morales et al., 1994, 1998). In a randomized, double-blind,
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placebo-controlled trial among 140 elderly men and 140
elderly women (60–79 years old), 50 mg of DHEA given
daily for 1 year reestablished circulating levels of DHEAS
and slightly increased levels of testosterone and estradiol.
The treatment led to improved bone turnover and skin
status, especially in women (Baulieu et al., 2000).
However, in spite of the numerous animal studies doc-
umenting beneficial effects of DHEA or DHEAS on ner-
vous functions and memory, most human trials have failed
to demonstrate an effect of DHEA on cognitive performance
in the elderly (Arlt et al., 2000; Wolf et al., 1997), except for
one study showing antidepressant and cognition-enhancing
effects in major depression (Wolkowitz et al., 1995).
10. Conclusions and perspectives
In the developed countries, the greater life expectancy and
the rapidly aging populations have increased the need for
health promotion in the elderly. In particular, the increas-
ing incidence and prevalence of cognitive impairment and
dementia, which will become one of the main causes of dis-
ability without medical progress, is a major public health
issue. A delay of their onset would already markedly reduce
their prevalence and would thus have an enormous impact on
health care expenditures and on the well-being of the elderly.
Preclinical research using a variety of animal models and
cell culture systems has provided promising results. They
indicate that the administration of steroids that support im-
portant neuronal and glial functions may protect the aging
nervous system, prevent the development of neurodegenera-
tive diseases and even reverse to some extent age-dependent
neuromorphological and cognitive changes. The main find-
ings reported in this review can be summarized as follows:
(1) during normal aging, there is no massive loss of neurons
in the brain; (2) the aging nervous system maintains capac-
ity for regeneration; (3) steroids have pleiotropic effects in
the nervous system, and they play important roles in the
viability of neurons, the maintenance and repair of myelin
sheaths and in cognitive processes, in particular in learning
and memory; (4) steroids present in nervous tissues originate
from the endocrine glands and from local synthesis (neu-
rosteroids); (5) the aging nervous system remains sensitive
to the protective effects of steroids; and (6) age-dependent
cognitive dysfunctions and alterations of the myelin sheaths
can be partially reversed by steroid administration. Together,
these findings strongly suggest that the use of steroids pro-
vides interesting therapeutical opportunities for promoting
successful aging.
In contrast to the wealth of preclinical findings reporting
beneficial effects of steroids on the nervous system, even in
aged animals, the results of clinical studies are not conclu-
sive. There is still no clear evidence for beneficial effects
of HRT on mood and cognitive functions in the elderly. Af-
ter the initial euphoria prompted by studies suggesting that
ERT in postmenopausal women may protect against the on-
set of AD and even improve cognitive functions in women
who already suffer from the disease, a series of studies have
questioned these beneficial effects of estrogen. Moreover,
recent results from a very large trial conducted by the WHI
have not only questioned the benefits of estrogen plus pro-
gestin therapy in postmenopausal women, but they have also
pointed to the risks. One reason for the outcome of this trial
may be related to the conditions of the treatment, and in
particular to the use of the synthetic progestin MPA, which
has been shown to have androgenic properties and to antag-
onize beneficial effects of estrogens on the cardiovascular
and nervous systems. Whether “pure” progestins, which do
not interfere with other steroid receptor systems, may exert
beneficial effects on the aging nervous system as strongly
suggested by animal studies is so far unknown. Concerning
two other steroids that, based on preclinical data, can be ex-
pected to play a significant role in the aging nervous system,
namely testosterone and DHEA, there is so far only limited
information.
The recent controversy concerning the potential benefits
and risks of steroid therapies in the elderly show that HRT,
although widely used, is still in its infancy. More controlled
clinical trials are urgently needed to evaluate the benefits and
risks of steroid treatments in the elderly. More information is
required concerning age-dependent changes of steroid lev-
els in the nervous system of normally aging and demented
patients of both sexes.
There is also need for the development of safer steroid
compounds with more selective and efficient actions on spe-
cific nervous functions. Selective estrogen and PR modu-
lators (SERMs and SPRMs), which have both agonist and
antagonist activities depending upon the site of their action
(mixed agonists/antagonists), offer interesting therapeutical
possibilities for the aging nervous system and may have ad-
vantages over current HRT because of their selective actions
and pharmacological characteristics. A variety of SERMs
have been developed recently with beneficial effects on neu-
rons and on cognitive functions (Barham, 2003; Chwalisz
et al., 2002; Dhandapani and Brann, 2002; Krishnan et al.,
2000; Littleton et al., 2002; Roe et al., 2000; Whitaker, 2001;
Yaffe, 2001).
Steroid enantiomers also offer interesting perspectives
for the treatment of age-dependent cognitive impairment or
neurodegenerative diseases. These are mirror-symmetric,
non-superimposable images of the molecules, with identical
physical properties (except for the different rotation of polar-
ized light; Covey et al., 2000). The synthetic (−)-enantiomer
of PREGS was 10 times more potent in activating mem-
ory functions than natural (+)-PREGS. This effect showed
enantiomeric selectivity: in contrast to (+)-PREGS, the
promnesic effects of (−)-PREGS could not be blocked by
a selective NMDA receptor antagonist (Akwa et al., 2001).
From the concept of neurosteroids derives another ther-
apeutical strategy: the use of pharmaceutical agents that
increase the synthesis of endogenous neurosteroids within
the nervous system. This approach is so far hampered by
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the lack of knowledge concerning the regulation of the
biosynthetic pathways of neurosteroids. Ligands of the
MBR have been shown to increase the synthesis of neuros-
teroids in cultured glioma cells (Papadopoulos et al., 1992)
and in the brain (Korneyev et al., 1993; Romeo et al., 1993;
Bitran et al., 2000). The possibility to increase the synthesis
of neuroactive steroids has stimulated recent efforts to de-
velop new more selective and efficient MBR ligands. Thus,
derivatives of 2-phenyl-imidazol[1,2]pyrimidine bind MBR
ligands with great affinity and selectivity, and when injected
intraperitoneally, they significantly increase brain neuros-
teroid levels in castrated and adrenalectomized rats, in
agreement with a stimulatory effect on brain neurosteroido-
genesis (Serra et al., 1999; Trapani et al., 1999). Among
the pharmaceutical agents that have been recently devel-
oped to influence neurosteroid levels in the brain are the
steroid sulfatase inhibitors. By increasing the accumulation
of neuroactive PREGS and DHEAS in the brain, they have
promnesic effects and reverse pharmacologically-induced
amnesia (Johnson et al., 1997; Li et al., 1995, 1997; Rhodes
et al., 1997).
Steroid therapy may become an important component of
preventive strategies against age-dependent cognitive dys-
functions, ranging from MCI to dementing diseases such as
AD. The development of safer and more selective steroid
receptor ligands, the targeting of alternative steroid signal-
ing pathways and the stimulation of neurosteroid synthe-
sis offer interesting possibilities for preventing and treating
age-dependent changes in nervous functions. However, it is
unlikely that steroids are sufficient and that they can substi-
tute for a healthful lifestyle, including intellectual activity,
exercise and diet, but they may make a valuable contribu-
tion to successful aging. During normal aging, steroids may
rather work as adjuvants by increasing the well-being of
the elderly and by stimulating brain mechanisms involved
in cognitive functions and motivation. Steroid replacement
therapy may be particularly effective in preserving vital ner-
vous functions in the case of severe hormone deficiencies.
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